Jane Holmes
Senior Clinical Trials Methodologist
Key publications
-
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
Journal article
Butler CC. et al, (2023), The Lancet, 401, 281 - 293
-
Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive Trial
Preprint
Butler C. et al, (2022)
-
Early phase clinical trials extension to guidelines for the content of statistical analysis plans
Journal article
Homer V. et al, (2022), The BMJ, 376
-
Visualising harms in publications of randomised controlled trials: consensus and recommendations.
Journal article
Phillips R. et al, (2022), BMJ, 377
Recent publications
-
Data from Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non–Small Cell Lung Cancer
Other
Skwarski M. et al, (2023)
-
Data from Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non–Small Cell Lung Cancer
Other
Skwarski M. et al, (2023)
-
Supplementary Data from Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non–Small Cell Lung Cancer
Other
Skwarski M. et al, (2023)
-
Supplementary Data from Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non–Small Cell Lung Cancer
Other
Skwarski M. et al, (2023)
-
Supplementary Data from Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non–Small Cell Lung Cancer
Other
Skwarski M. et al, (2023)